宫颈癌新辅助化疗前后uPA、VEGF和Ki-67的表达及其临床意义  

Expression of uPA,VEGF and Ki-67 in Cervical Cancer before and after Neoadjuvant Chemotherapy and Its Clinical Significance

作　　者：刘嵘[1] 李天[1] 何泓[1] 濮德敏[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院妇产科,武汉430030

出　　处：《华中科技大学学报（医学版）》2013年第6期712-714,共3页Acta Medicinae Universitatis Scientiae et Technologiae Huazhong

摘　　要：目的探讨新辅助化疗对宫颈鳞状细胞癌组织中尿激酶型纤溶酶原激活物（uPA）、血管内皮生长因子（VEGF）和肿瘤细胞增殖指数Ki-67表达的影响,并分析其表达变化与临床疗效的关系。方法用免疫组化SP法分别检测58例ⅠB2~ⅡB期宫颈鳞癌患者新辅助化疗前后uPA、VEGF、Ki-67的表达。结果新辅助化疗后,uPA、VEGF及Ki-67的表达均明显下降（均P〈0.05）;化疗前uPA、VEGF阴性患者的化疗效果优于uPA、VEGF阳性者（均P〈0.05）,化疗前Ki-67阳性表达的患者新辅助化疗效果明显好于阴性表达者（P〈0.01）。结论 uPA、VEGF、Ki-67的表达变化与宫颈癌新辅助化疗疗效显著相关,有可能作为预测宫颈癌新辅助化疗效果的参考指标。Objective To examine the effect of neoadjuvant chemotherapy on the expression of uPA,VEGF and Ki-67 in cervical squamous cell carcinoma tissues and analyze the association of the expression change with the clinical efficacy.Methods The expression of uPA,VEGF and Ki-67 was immunohistochemically determined in 58cases ofⅠB2-ⅡB stage cervical squamous carcinoma before and after neoadjuvant chemotherapy.Results After neoadjuvant chemotherapy,the expression of uPA, VEGF,Ki-67was significantly decreased（P0.05）.The effect of neoadjuvant chemotherapy was better in patients with negative expression of uPA and VEGF before treatment（P0.05）.Patients with high expression of Ki-67 responded well to neoadjuvant chemotherapy（P0.01）.Conclusion The expression of uPA,VEGF and Ki-67protein is closely associated with clinical effects of neoadjuvant chemotherapy,which may become new markers for prediction of the efficacy of neoadjuvant chemotherapy.

关 键 词：宫颈癌 新辅助化疗 尿激酶型纤溶酶原激活物 血管内皮生长因子 KI-67 

分 类 号：R737.33[医药卫生—肿瘤]